Ronacaleret does not significantly reduce time to healing of distal radius fracture .
This report has been verified
by one or more authors of the
original publication.
Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, double-blinded, placebo-controlled Phase II clinical trial
Bone. 2011 Oct;49(4):845-52. doi: 10.1016/j.bone.2011.06.017. Epub 2011 Jun 3085 patients were randomized to determine the effect of orally administered ronacaleret, a calcium-sensing receptor antagonist, on distal radius fracture healing. Patients were prescribed either 200mg ronacaleret twice daily, 400mg ronacaleret once daily, or a placebo for 12 weeks. The results indicated neither ronacaleret regimen significantly reduced time to radiographic healing of the fracture, despite increasing serum levels of bone formation markers. Incidence of hypercalcium was noted with the 200mg ronacaleret twice daily regimen. The study was terminated early due to futility based on 50% conditional power.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
